The effects of cilazapril alone and in combination with frusemide in healthy subjects

Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):235S-242S. doi: 10.1111/j.1365-2125.1989.tb03487.x.

Abstract

1. In a fourway double-blind placebo controlled study, the effects of cilazapril, a new angiotensin converting enzyme inhibitor, on renal function and the responses to intravenous frusemide were studied in a group of twelve salt depleted male volunteers. 2. Cilazapril produced an increase in effective renal plasma flow and urinary output of prostaglandin E2 metabolite (PGE2-M) but no effect on sodium, potassium or water excretion. 3. Pretreatment with cilazapril antagonised the effects of frusemide on glomerular filtration, PGE2-M and sodium excretion.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Cilazapril
  • Dinoprostone / urine
  • Double-Blind Method
  • Furosemide / administration & dosage
  • Furosemide / pharmacology*
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Injections, Intravenous
  • Kidney / drug effects*
  • Male
  • Pyridazines / administration & dosage
  • Pyridazines / pharmacology*
  • Renin / blood

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Pyridazines
  • Cilazapril
  • Furosemide
  • Renin
  • Dinoprostone